Median TechnologiesEURONEXT: ALMDT

Median Technologies: H2 2026 Financial Communication Calendar

· Issued by Median Technologies via Business Wire

Summary by 6ix AI

Median Technologies, a French developer of AI-powered medical software for early cancer detection and provider of imaging services for cancer drug developers, set its financial calendar for the second half of 2026, with first-half 2026 results due October 29, 2026, after market close.

Key details

  • Median will take part in the European MidCap Event 2026 in Paris, France, from September 30 to October 1, 2026.
  • Median will take part in the Investor Access Conference 2026 in Paris, France, on October 6-7, 2026.
  • Median will take part in the Portzamparc Biotech and Healthcare Sector Investor Seminar, held online, on October 14-15, 2026.
  • The investor events are for institutional investors only, and meetings with Median management are requested through each event's booking system.

6ix AI wrote this summary from the release below and checked it against the release.

SOPHIA ANTIPOLIS, France, September 10, 2026--(BUSINESS WIRE)--Regulatory News:

Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, "Median" or the "Company"), developer of eyonis®, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer detection and diagnosis, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, announced today its H2 2026 financial communication calendar.

Date

H1 2026 results

October 29, 2026, release
after market close

The Company will participate in upcoming investor events:

European MidCap Event 2026 - September 30 – October 1st, 2026 - Paris, France

Investor Access Conference 2026 - October 6-7, 2026 - Paris, France

Portzamparc Biotech and Healthcare Sector Investor Seminar - October 14-15, 2026 (digital)

Please get in touch through the respective event booking systems, if you would like to request a meeting with Median management at these events. Events are for institutional investors only.

About Median Technologies: Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis®, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit www.mediantechnologies.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260910527817/en/

Contacts

MEDIAN TECHNOLOGIES
Emmanuelle Leygues
VP, Corporate Marketing
& Financial Communications
+33 6 10 93 58 88
emmanuelle.leygues@mediantechnologies.com

Investors - SEITOSEI ACTIFIN
Ghislaine Gasparetto
+33 6 85 36 76 81
ghislaine.gasparetto@seitosei-actifin.com

Media – MAARC
Bruno Arabian
+33 6 87 88 47 26
bruno.arabian@maarc.fr

View original source (Business Wire)Median Technologies on 6ix

Story so far

Earlier from Median Technologies

Later from Median Technologies

All Median Technologies news releases